Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients

N Engl J Med. 1998 May 14;338(20):1413-21. doi: 10.1056/NEJM199805143382003.


Background: Epstein-Barr virus (EBV) is associated with various malignant and benign lymphoproliferative disorders. It also efficiently transforms human B lymphocytes in vitro. The latent membrane protein 1 (LMP1) of EBV-infected cells plays a central part in this process by mimicking members of the family of tumor necrosis factor (TNF) receptors, thereby transmitting growth signals from the cell membrane to the nucleus through cytoplasmic TNF-receptor-associated factors (TRAFs). I sought evidence of LMP1-mediated signal transduction through TRAFs in tumor tissue from patients with post-transplantation lymphoproliferative disease and non-Hodgkin's lymphomas related to the acquired immunodeficiency syndrome (AIDS).

Methods: The association of LMP1 with TRAF-1 or TRAF-3 in tumor tissue was studied with double-immunofluorescence microscopy and immunoprecipitation assays. Evidence of LMP1-TRAF signaling was sought with an electrophoretic mobility shift assay for the nuclear factor-kappaB (NF-kappaB) transcription factor.

Results: Tumors from eight patients with post-transplantation lymphoproliferative disease, two patients with AIDS-associated non-Hodgkin's lymphoma, and three patients with endemic Burkitt's lymphoma were analyzed. Tumors from six of the patients with post-transplantation lymphoproliferative disease were positive for EBV and expressed LMP1; two samples were EBV-negative. Tumors from both patients with AIDS-associated non-Hodgkin's lymphoma were EBV-positive and expressed LMP1, whereas tumors from all three patients with Burkitt's tumors were positive for EBV but negative for LMP1. Double-immunofluorescence microscopy showed that LMP1 localized with and immunoprecipitated with TRAF-1 and TRAF-3 in all eight of the EBV-positive, LMP1-positive samples. An electrophoretic mobility shift assay revealed activated NF-kappaB in all eight EBV-positive, LMP1-positive samples as well, but not in either of the EBV-negative, LMP1-negative samples or in the three EBV-positive, LMP1-negative samples.

Conclusions: LMP1-mediated signaling through the TRAF system has a role in the pathogenesis of the EBV-positive lymphomas that arise in immunosuppressed patients.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications
  • Gene Expression
  • Herpesvirus 4, Human / genetics
  • Herpesvirus 4, Human / physiology*
  • Humans
  • Immunocompromised Host
  • Lymphoma, Non-Hodgkin / etiology
  • Lymphoma, Non-Hodgkin / metabolism*
  • Lymphoma, Non-Hodgkin / virology
  • Lymphoproliferative Disorders / etiology
  • Lymphoproliferative Disorders / metabolism*
  • Lymphoproliferative Disorders / virology
  • Microscopy, Fluorescence
  • NF-kappa B / metabolism
  • Proteins / physiology*
  • Signal Transduction*
  • TNF Receptor-Associated Factor 1
  • TNF Receptor-Associated Factor 3
  • Transplantation / adverse effects
  • Viral Matrix Proteins / physiology*


  • EBV-associated membrane antigen, Epstein-Barr virus
  • NF-kappa B
  • Proteins
  • TNF Receptor-Associated Factor 1
  • TNF Receptor-Associated Factor 3
  • Viral Matrix Proteins